Categories: NewsPharmaceutical

Magnet Biomedicine Selects Simplicis’s Ledger™ Platform to Lead Innovation in Compound Management

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

BOSTON, March 4, 2025 /PRNewswire/ — Magnet Biomedicine, a biotechnology company advancing molecular glue discovery through rational selection and design, has selected Simplicis’s Ledger™ platform after a rigorous evaluation process that considered several leading competitors. Simplicis’s unmatched combination of innovation, adaptability, and cost-efficiency proved to be the ideal choice to support Magnet’s cutting-edge research operations.

Magnet Biomedicine is recognized for its TrueGlue™ discovery platform, which leverages advancements in human biology and proteomics to develop next-generation molecular glues targeting critical unmet medical needs. Choosing Simplicis’s Ledger™ platform enables Magnet to advance its mission to deliver transformative therapeutic solutions.

Strategic Decision to Partner with Simplicis

Liam Hudson, Associate Director at Magnet Biomedicine, explained the decision-making process:

“After evaluating multiple platforms, it was clear that Simplicis offered a combination of Functionality, technical knowledge and value that others could not match. Ledger™ stood out as the solution that best aligns with our operational needs and future growth.

Hudson also emphasized the importance of collaboration and innovation:

“Simplicis’s pragmatic and forward-thinking approach equips us with the tools to enhance our compound management capabilities and scale efficiently.”

Driving Operational Efficiency with Advanced Technology

Gina Chen, Compound Management Lead at Magnet Biomedicine, highlighted the user-centric design and adaptability of Simplicis’s Ledger™ platform:

“Ledger™ delivers all the features we needed—and more—in a streamlined, user-friendly interface. Its ability to support pre-validation of requests ensures accountability and simplifies workflows across teams.”

Chen also noted the impact of advanced automation on team productivity:

“With Simplicis, we’ve seen a significant reduction in manual tasks, allowing us to focus on the science rather than the logistics.”

Integration and Flexibility as Key Differentiators

James Ralff, Research Associate at Magnet Biomedicine, praised Ledger™ seamless integration capabilities:

“Ledger™ integrates effortlessly with our existing workflows, offering intuitive tools that simplify data management and enable us to work more efficiently.”

Ralff highlighted the platform’s ability to handle complex workflows:

“Simplicis’s capabilities empower us to mine data effectively, streamline plate mapping, and optimize our processes in ways that were previously unattainable.”

Implementation and Looking Ahead

Magnet Biomedicine has already begun its transition to the Ledger™ platform, with a full go-live expected in February 2025. The implementation process includes migrating legacy systems, integrating key hardware, and training staff to leverage the platform’s full potential. The partnership is expected to drive significant operational efficiencies, enhance collaboration, and provide a strong foundation for future growth.

About Magnet Biomedicine

Magnet Biomedicine is a biotechnology company advancing molecular glue discovery through rational selection and design. The company’s TrueGlue™ discovery platform integrates cutting-edge science and technology to develop therapeutic solutions that address critical unmet medical needs, offering transformative potential for precision medicine.

For more information, visit magnetbio.com.

About Simplicis

Simplicis is a leading provider of laboratory information management systems (LIMS) designed to optimize workflows, enhance data management, and drive innovation. The Ledger™ platform is a state-of-the-art solution tailored to meet the evolving needs of the biotechnology and pharmaceutical sectors, delivering efficiency and scalability for research organizations worldwide.

For more information, visit simplicis.com

Media Contact:
Jennifer Franklin
Vice President of Administration & Operations
Magnet Biomedicine
info@magnetbio.com
(617) 741-0974

View original content to download multimedia:https://www.prnewswire.com/news-releases/magnet-biomedicine-selects-simpliciss-ledger-platform-to-lead-innovation-in-compound-management-302391921.html

SOURCE Simplicis

Staff

Recent Posts

TEN RESEARCHERS HONORED AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE

TORONTO, July 27, 2025 /PRNewswire/ -- The Alzheimer's Association® will present 10 scientific awards at…

14 hours ago

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel…

2 days ago

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP)…

2 days ago

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

2 days ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”)…

2 days ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”)…

2 days ago